Handelen Exact Sciences Corporation - EXAS CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 0.81 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.024874% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.002651% | ||||||||
Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Exact Sciences Corp ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 66.19 |
Open* | 65.63 |
1-Jaarlijkse Verandering* | -7.65% |
Dagelijks bereik* | 65.63 - 68.17 |
52 wekelijks bereik | 29.27-76.94 |
Weekgemiddelde volume (10 dagen) | 1.77M |
Gemiddeld volume (3 maanden) | 51.75M |
Marktkapitalisatie | 11.96B |
P/E Ratio | -100.00K |
Uitstaande Aandelen | 178.22M |
Omzet | 2.08B |
EPS | -3.54 |
Dividend (opbrengst %) | N/A |
Beta | 1.40 |
Volgende inkomsten datum | Apr 24, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Mar 30, 2023 | 66.19 | -1.09 | -1.62% | 67.28 | 67.54 | 65.53 |
Mar 29, 2023 | 67.01 | -0.01 | -0.01% | 67.02 | 68.02 | 65.93 |
Mar 28, 2023 | 66.00 | -0.10 | -0.15% | 66.10 | 66.80 | 65.24 |
Mar 27, 2023 | 66.47 | 0.43 | 0.65% | 66.04 | 67.92 | 65.87 |
Mar 24, 2023 | 65.92 | 1.89 | 2.95% | 64.03 | 66.21 | 63.46 |
Mar 23, 2023 | 65.30 | 1.01 | 1.57% | 64.29 | 67.91 | 64.12 |
Mar 22, 2023 | 64.11 | -1.68 | -2.55% | 65.79 | 66.85 | 63.73 |
Mar 21, 2023 | 66.36 | 2.76 | 4.34% | 63.60 | 66.74 | 63.60 |
Mar 20, 2023 | 63.06 | -0.06 | -0.10% | 63.12 | 64.40 | 62.34 |
Mar 17, 2023 | 63.10 | -1.85 | -2.85% | 64.95 | 65.32 | 62.78 |
Mar 16, 2023 | 65.87 | 2.18 | 3.42% | 63.69 | 66.35 | 63.08 |
Mar 15, 2023 | 64.25 | 0.55 | 0.86% | 63.70 | 64.27 | 62.05 |
Mar 14, 2023 | 64.12 | -0.32 | -0.50% | 64.44 | 65.00 | 63.11 |
Mar 13, 2023 | 63.28 | 1.08 | 1.74% | 62.20 | 65.61 | 61.34 |
Mar 10, 2023 | 61.94 | -0.97 | -1.54% | 62.91 | 64.39 | 60.87 |
Mar 9, 2023 | 64.43 | -3.33 | -4.91% | 67.76 | 68.19 | 64.13 |
Mar 8, 2023 | 64.91 | 0.00 | 0.00% | 64.91 | 67.00 | 64.60 |
Mar 7, 2023 | 65.76 | -0.62 | -0.93% | 66.38 | 67.70 | 65.67 |
Mar 6, 2023 | 66.97 | -0.88 | -1.30% | 67.85 | 69.36 | 66.43 |
Mar 3, 2023 | 67.23 | 3.53 | 5.54% | 63.70 | 67.74 | 63.51 |
Exact Sciences Corporation Events
Tijd (UTC) (UTC) | Land | Evenement |
---|---|---|
No events scheduled |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totale inkomsten | 2084.28 | 1767.09 | 1491.39 | 876.293 | 454.462 |
Inkomsten | 2084.28 | 1767.09 | 1491.39 | 876.293 | 454.462 |
Kosten van opbrengsten, totaal | 574.394 | 458.757 | 354.324 | 216.717 | 116.644 |
Brutowinst | 1509.89 | 1308.33 | 1137.07 | 659.576 | 337.818 |
Totale bedrijfskosten | 2677.79 | 2622.76 | 2259.09 | 1110.07 | 613.933 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 1583.31 | 1663.15 | 1071.31 | 737.629 | 427.464 |
Onderzoek & Ontwikkeling | 393.418 | 300.346 | 141.452 | 139.694 | 67.285 |
Bedrijfsresultaat | -593.511 | -855.678 | -767.696 | -233.782 | -159.471 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -39.059 | 13.172 | -61.367 | -172.662 | -15.586 |
Netto inkomen voor belastingen | -632.57 | -842.506 | -829.063 | -406.444 | -175.057 |
Netto inkomen na belastingen | -623.506 | -595.625 | -823.605 | -213.09 | -175.149 |
Netto inkomen voor extra. Posten | -623.506 | -595.625 | -823.605 | -213.09 | -175.149 |
Netto inkomen | -623.506 | -595.625 | -823.605 | -213.09 | -175.149 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -623.506 | -595.625 | -823.605 | -213.09 | -175.149 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -623.506 | -595.625 | -823.605 | -213.09 | -175.149 |
Verwaterd Netto Inkomen | -623.506 | -595.625 | -823.605 | -213.09 | -175.149 |
Verwaterd Gewogen Gemiddelde Aandelen | 176.351 | 171.348 | 151.137 | 131.257 | 122.207 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -3.5356 | -3.47611 | -5.44939 | -1.62346 | -1.43322 |
Verwaterde Genormaliseerde Winst per Aandeel | -3.47674 | -3.07587 | -2.77319 | -1.62346 | -1.43322 |
Depreciation / Amortization | 97.45 | 95.001 | 93.398 | 16.035 | 2.54 |
Ongebruikelijke uitgaven (inkomsten) | 15.969 | 105.51 | 622.266 | 0 | |
Other Operating Expenses, Total | 13.244 | 0 | -23.665 | 0 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Totale inkomsten | 552.995 | 523.073 | 521.64 | 486.571 | 473.812 |
Inkomsten | 552.995 | 523.073 | 521.64 | 486.571 | 473.812 |
Kosten van opbrengsten, totaal | 147.152 | 147.937 | 144.6 | 134.705 | 119.058 |
Brutowinst | 405.843 | 375.136 | 377.04 | 351.866 | 354.754 |
Totale bedrijfskosten | 671.877 | 661.131 | 681.224 | 663.558 | 695.262 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 404.105 | 379.665 | 397.594 | 401.951 | 463.669 |
Onderzoek & Ontwikkeling | 94.274 | 90.813 | 106.083 | 102.248 | 40.9 |
Depreciation / Amortization | 22.914 | 23.526 | 26.356 | 24.654 | 24.047 |
Ongebruikelijke uitgaven (inkomsten) | 3.432 | 5.946 | 6.591 | 85.3 | |
Bedrijfsresultaat | -118.882 | -138.058 | -159.584 | -176.987 | -221.45 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -11.045 | -13.819 | -8.23 | -5.965 | -3.404 |
Netto inkomen voor belastingen | -129.927 | -151.877 | -167.814 | -182.952 | -224.854 |
Netto inkomen na belastingen | -127.745 | -148.761 | -166.063 | -180.937 | -220.611 |
Netto inkomen voor extra. Posten | -127.745 | -148.761 | -166.063 | -180.937 | -220.611 |
Netto inkomen | -127.745 | -148.761 | -166.063 | -180.937 | -220.611 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -127.745 | -148.761 | -166.063 | -180.937 | -220.611 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -127.745 | -148.761 | -166.063 | -180.937 | -220.611 |
Verwaterd Netto Inkomen | -127.745 | -148.761 | -166.063 | -180.937 | -220.611 |
Verwaterd Gewogen Gemiddelde Aandelen | 177.599 | 176.997 | 176.364 | 174.417 | 172.458 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.71929 | -0.84047 | -0.94159 | -1.03738 | -1.27922 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Verwaterde Genormaliseerde Winst per Aandeel | -0.70673 | -0.81864 | -0.9173 | -1.03738 | -0.95772 |
Other Operating Expenses, Total | 0 | 13.244 | -37.712 |
- Jaarlijks
- Per kwartaal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Totaal vlottende activa | 1426.24 | 2198.59 | 553.936 | 1228.07 | 487.216 |
Geldmiddelen en kortetermijnbeleggingen | 1030.48 | 1839.99 | 323.655 | 1124.18 | 424.715 |
Geldmiddelen & Equivalenten | 68.136 | 1491.29 | 177.254 | 160.43 | 77.491 |
Korte Termijn Investeringen | 715.005 | 348.699 | 146.401 | 963.752 | 347.224 |
Totale Vorderingen, Netto | 216.645 | 233.185 | 130.362 | 44.239 | 26.419 |
Accounts Receivable - Trade, Net | 216.645 | 233.185 | 130.362 | 44.239 | 26.419 |
Total Inventory | 104.994 | 92.265 | 61.724 | 39.148 | 26.027 |
Prepaid Expenses | 74.122 | 33.157 | 38.195 | 20.498 | 10.055 |
Total Assets | 6684.88 | 4925.09 | 3505.77 | 1524.02 | 598.56 |
Property/Plant/Equipment, Total - Net | 772.673 | 596.533 | 582.069 | 245.259 | 79.986 |
Property/Plant/Equipment, Total - Gross | 987.489 | 734.07 | 659.7 | 303.121 | 118.072 |
Accumulated Depreciation, Total | -214.816 | -137.537 | -77.631 | -57.862 | -38.086 |
Other Long Term Assets, Total | 56.391 | 45.17 | 23.016 | 4.415 | 9.198 |
Total Current Liabilities | 517.068 | 633.095 | 236.494 | 136.169 | 68.124 |
Accounts Payable | 67.829 | 35.709 | 25.973 | 28.141 | 16.135 |
Accrued Expenses | 418.266 | 245.087 | 201.22 | 104.816 | 49.126 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 6.2 | 318.734 | 0.866 | 0.008 | 0.182 |
Other Current Liabilities, Total | 24.773 | 33.565 | 8.435 | 3.204 | 2.681 |
Total Liabilities | 3297.25 | 2689.54 | 1217.71 | 843.081 | 78.142 |
Total Long Term Debt | 2192.73 | 1898.03 | 827.837 | 689.243 | 4.269 |
Long Term Debt | 2180.23 | 1884.03 | 827.637 | 689.243 | 4.269 |
Other Liabilities, Total | 587.448 | 158.417 | 153.376 | 17.669 | 5.749 |
Total Equity | 3387.64 | 2235.55 | 2288.06 | 680.941 | 520.418 |
Common Stock | 1.738 | 1.595 | 1.477 | 1.232 | 1.205 |
Additional Paid-In Capital | 6028.86 | 4279.33 | 3406.44 | 1716.89 | 1380.58 |
Retained Earnings (Accumulated Deficit) | -2641.52 | -2045.9 | -1119.76 | -1035.76 | -860.614 |
Unrealized Gain (Loss) | -1.466 | 0.526 | -0.075 | -1.397 | -0.689 |
Other Equity, Total | 0.023 | 0 | -0.025 | -0.025 | -0.061 |
Total Liabilities & Shareholders’ Equity | 6684.88 | 4925.09 | 3505.77 | 1524.02 | 598.56 |
Total Common Shares Outstanding | 173.674 | 159.423 | 147.626 | 123.193 | 120.497 |
Intangibles, Net | 2094.41 | 847.123 | 1143.55 | 29.002 | 22.16 |
Goodwill, Net | 2335.17 | 1237.67 | 1203.2 | 17.279 | |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Capital Lease Obligations | 12.5 | 14 | 0.2 | ||
Cash | 247.335 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totaal vlottende activa | 1215.14 | 1426.24 | 1615.59 | 1669.21 | 1775.3 |
Geldmiddelen en kortetermijnbeleggingen | 816.98 | 1030.48 | 1218.47 | 1307.58 | 1377.97 |
Cash | 135.32 | 247.335 | 273.779 | 360.797 | 770.267 |
Geldmiddelen & Equivalenten | 54.456 | 68.136 | 0 | 2.918 | 333.549 |
Korte Termijn Investeringen | 627.204 | 715.005 | 944.688 | 943.864 | 274.151 |
Totale Vorderingen, Netto | 205.625 | 216.645 | 249.572 | 226.539 | 256.135 |
Accounts Receivable - Trade, Net | 205.625 | 216.645 | 249.572 | 226.539 | 256.135 |
Total Inventory | 112.958 | 104.994 | 95.167 | 89.809 | 89.033 |
Prepaid Expenses | 79.575 | 74.122 | 52.385 | 45.284 | 52.167 |
Total Assets | 6490.54 | 6684.88 | 6654.44 | 6724.33 | 6734.52 |
Property/Plant/Equipment, Total - Net | 810.386 | 772.673 | 710.811 | 687.022 | 644.423 |
Property/Plant/Equipment, Total - Gross | 1047.52 | 987.489 | 906.098 | 860.748 | 801.063 |
Accumulated Depreciation, Total | -237.131 | -214.816 | -195.287 | -173.726 | -156.64 |
Goodwill, Net | 2335.17 | 2335.17 | 2242.53 | 2242.53 | 2183.92 |
Intangibles, Net | 2069.76 | 2094.41 | 2044.96 | 2089.11 | 2073.93 |
Other Long Term Assets, Total | 60.084 | 56.391 | 40.541 | 36.458 | 56.945 |
Total Current Liabilities | 480.952 | 517.068 | 710.231 | 675.698 | 628.914 |
Accounts Payable | 66.471 | 67.829 | 41.717 | 36.592 | 34.704 |
Accrued Expenses | 385.627 | 418.266 | 323.934 | 282.596 | 229.433 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 6.4 | 6.2 | 320.323 | 319.68 | 314.151 |
Other Current Liabilities, Total | 22.454 | 24.773 | 24.257 | 36.83 | 50.626 |
Total Liabilities | 3232.33 | 3297.25 | 3196.85 | 3165.23 | 3085.52 |
Total Long Term Debt | 2193.28 | 2192.73 | 1900.29 | 1899.15 | 1885.03 |
Long Term Debt | 2181.68 | 2180.23 | 1887.08 | 1886.05 | 1885.03 |
Other Liabilities, Total | 558.094 | 587.448 | 586.33 | 590.383 | 571.575 |
Total Equity | 3258.21 | 3387.64 | 3457.59 | 3559.1 | 3649 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 1.757 | 1.738 | 1.723 | 1.72 | 1.714 |
Additional Paid-In Capital | 6085.56 | 6028.86 | 5876.64 | 5811.29 | 5723.98 |
Retained Earnings (Accumulated Deficit) | -2822.46 | -2641.52 | -2420.91 | -2253.97 | -2077.06 |
Unrealized Gain (Loss) | -6.433 | -1.466 | 0.133 | 0.067 | 0.364 |
Total Liabilities & Shareholders’ Equity | 6490.54 | 6684.88 | 6654.44 | 6724.33 | 6734.52 |
Total Common Shares Outstanding | 175.551 | 173.674 | 172.243 | 171.855 | 171.293 |
Capital Lease Obligations | 11.6 | 12.5 | 13.2 | 13.1 | |
Other Equity, Total | -0.214 | 0.023 |
- Jaarlijks
- Per kwartaal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | -595.625 | -848.533 | -83.993 | -175.149 | -114.397 |
Geldmiddelen uit Operationele Activiteiten | -102.236 | 136.482 | -111.655 | -68.94 | -71.724 |
Geldmiddelen uit Operationele Activiteiten | 85.345 | 69.964 | 34.212 | 20.544 | 14.5 |
Amortization | 95.001 | 93.398 | 16.035 | 2.54 | 1.055 |
Niet-Geldelijke Posten | 455.103 | 874.244 | 160.756 | 83.271 | 34.911 |
Contant Betaalde Rente | 10.735 | 9.384 | 5.128 | 4.638 | 0.201 |
Veranderingen in het Operationeel Kapitaal | 111.109 | -42.729 | -53.556 | -0.911 | -7.678 |
Geldmiddelen uit Investeringsactiviteiten | -1082.08 | -702.037 | -124.428 | -782.299 | -160.805 |
Kapitaaluitgaven | -193.839 | -476.154 | -172.654 | -150.671 | -69.24 |
Overige Cash Flow investeringsposten, Totaal | -888.246 | -225.883 | 48.226 | -631.628 | -91.565 |
Geldmiddelen uit Financieringsactiviteiten | 8.472 | 1879.62 | 253.181 | 934.142 | 260.956 |
Financiering van Cash Flow Posten | 17.784 | 15.35 | 7.954 | 6.84 | 2.639 |
Uitgifte (Aflossing) van aandelen, netto | 14.437 | 888.778 | 8.787 | 6.636 | 258.491 |
Uitgifte (Aflossing) van Schulden, Netto | -23.749 | 975.493 | 236.44 | 920.666 | -0.174 |
Wisselkoerseffecten | 0.023 | 0 | 0 | 0.036 | 0.143 |
Nettowijziging in Geldmiddelen | -1175.83 | 1314.07 | 17.098 | 82.939 | 28.57 |
Deferred Taxes | -253.169 | -9.862 | -185.109 | 0.765 | -0.115 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -180.937 | -595.625 | -375.014 | -208.076 | -31.164 |
Cash From Operating Activities | -173.754 | -102.236 | -77.664 | -36.89 | -77.227 |
Cash From Operating Activities | 22.993 | 85.345 | 64.267 | 42.007 | 20.508 |
Amortization | 24.654 | 95.001 | 70.954 | 47.014 | 23.19 |
Deferred Taxes | -1.912 | -253.169 | -248.716 | -244.509 | -243.13 |
Non-Cash Items | 37.451 | 455.103 | 393.598 | 293.463 | 191.036 |
Cash Interest Paid | 5.133 | 10.735 | 10.685 | 5.414 | 5.274 |
Changes in Working Capital | -76.003 | 111.109 | 17.247 | 33.211 | -37.667 |
Cash From Investing Activities | 45.561 | -1082.08 | -1160.52 | -1111.28 | -317.512 |
Capital Expenditures | -33.623 | -193.839 | -134.447 | -95.577 | -37.92 |
Other Investing Cash Flow Items, Total | 79.184 | -888.246 | -1026.07 | -1015.7 | -279.592 |
Cash From Financing Activities | 2.735 | 8.472 | 20.668 | 20.587 | 7.245 |
Financing Cash Flow Items | -1.547 | 17.784 | 7.296 | 8.97 | -1.514 |
Issuance (Retirement) of Stock, Net | 4.282 | 14.437 | 13.372 | 11.617 | 8.759 |
Issuance (Retirement) of Debt, Net | -23.749 | 0 | 0 | 0 | |
Net Change in Cash | -125.695 | -1175.83 | -1217.52 | -1127.58 | -387.494 |
Foreign Exchange Effects | -0.237 | 0.023 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.6331 | 17167785 | 568715 | 2022-12-31 | LOW |
ARK Investment Management LLC | Investment Advisor | 9.0005 | 16040490 | -1521212 | 2022-12-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 5.7525 | 10251938 | -975696 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.056 | 7228471 | 589454 | 2022-12-31 | LOW |
JP Morgan Asset Management | Investment Advisor | 3.4041 | 6066647 | 2387332 | 2022-12-31 | LOW |
Sumitomo Mitsui Trust Bank, Limited | Bank and Trust | 3.0101 | 5364599 | -1152546 | 2022-12-31 | LOW |
Capital World Investors | Investment Advisor | 2.913 | 5191387 | 197698 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.9059 | 5178803 | -151946 | 2022-12-31 | LOW |
Baillie Gifford & Co. | Investment Advisor | 2.767 | 4931262 | 118025 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.7395 | 4882189 | -820459 | 2022-12-31 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 1.647 | 2935291 | -2593 | 2022-12-31 | MED |
Ensign Peak Advisors, Inc. | Foundation | 1.46 | 2601887 | 988811 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.4023 | 2499174 | 126538 | 2022-12-31 | LOW |
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 1.3548 | 2414533 | -558111 | 2022-12-31 | LOW |
Artisan Partners Limited Partnership | Investment Advisor | 1.2182 | 2171093 | 1107474 | 2022-12-31 | LOW |
Invesco Advisers, Inc. | Investment Advisor | 1.0661 | 1899987 | 9924 | 2022-12-31 | LOW |
Eventide Asset Management, LLC | Investment Advisor | 1.0478 | 1867365 | 0 | 2022-12-31 | MED |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 0.8738 | 1557200 | -4792 | 2022-12-31 | LOW |
Armistice Capital LLC | Hedge Fund | 0.8619 | 1536000 | -24000 | 2022-12-31 | HIGH |
Zevenbergen Capital Investments LLC | Investment Advisor | 0.7773 | 1385328 | -100920 | 2022-12-31 | MED |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group500K+
Handelaren
92K+
Actieve klanten per maand
$53M+
Maandelijks beleggingsvolume
$30M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
EXACT Sciences Company profile
Over Exact Sciences Corporation
Exact Sciences Corporation is een wereldwijd bedrijf voor kankerdiagnostiek. Het bedrijf levert een portfolio van producten voor vroegere opsporing van kanker. Het biedt laboratoriumtestdiensten aan van zijn Cologuard colorectale kankerscreeningtest, Oncotype DX kankerdiagnosetests en -diensten, en COVID-19 test. Het belangrijkste screeningproduct, de Cologuard-test, is een niet-invasieve, op ontlasting gebaseerde desoxyribonucleïnezuur (sDNA)-screeningtest die gebruik maakt van een multi-targetbenadering om DNA- en hemoglobinebiomarkers op te sporen die in verband worden gebracht met colorectale kanker en pre-kanker. De portefeuille van Oncotype-tests bestaat uit Oncotype DX-genexpressietests voor borst-, prostaat- en colonkanker; Oncotype DX AR-V7 Nucleus Detect-test, een vloeistofgebaseerde test voor prostaatkanker in een gevorderd stadium; Oncotype MAPTM Pan-Cancer Tissue-test; en GEM ExTra-test. Het bedrijf ontwikkelt een biomarkertest op bloedbasis die moet dienen als alternatief voor echografie en alfa-foetoproteïne (AFP) bij het testen van hepatocellulair carcinoom (HCC).
Industry: | Bio Diagnostics & Testing |
5505 Endeavor Lane
MADISON
WISCONSIN 53719
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen